Skip to content

Celldex Therapeutics CLDX Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Amgen logo
AmgenAMGN
Incyte logo
IncyteINCY
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH

Other financials

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.59B+75.2%
Enterprise value$2.55B+74.4%
P/S2,989.2×+2,794×

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0.0×
Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celldex Therapeutics's accrued liabilities, current?
Celldex Therapeutics (CLDX) reported accrued liabilities, current of $38.42M in Q1 2026.
How has Celldex Therapeutics's accrued liabilities, current changed year-over-year?
Celldex Therapeutics's accrued liabilities, current increased by 50.9% year-over-year, from $25.46M to $38.42M.
What is the long-term trend for Celldex Therapeutics's accrued liabilities, current?
Over 5 years (2020 to 2025), Celldex Therapeutics's accrued liabilities, current has grown at a 40.9% compound annual growth rate (CAGR), from $8.46M to $47.03M.